Proteins, I.e., More Than 100 Amino Acid Residues Patents (Class 530/350)
  • Patent number: 10251941
    Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: April 9, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Michel Canavaggio
  • Patent number: 10233228
    Abstract: The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: March 19, 2019
    Assignee: ALBUMEDIX LTD
    Inventors: Andrew Plumridge, Darrell Sleep, Inger Sandlie, Jan Terje Andersen, Jason Cameron, Leslie Evans, Steven Athwal, Elizabeth Allan, Esben Peter Friis
  • Patent number: 10227386
    Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: March 12, 2019
    Assignee: Entos Pharmaceuticals Inc.
    Inventors: Roy Duncan, Eileen Kathryn Clancy, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt
  • Patent number: 10226431
    Abstract: Microbiota restoration therapy (MRT) compositions (e.g., oral MRT compositions) and methods for manufacturing MRT compositions are disclosed. An example method for manufacturing an MRT composition may include collecting a stool sample, purifying the stool sample to form a purified sample, stabilizing the purified sample to form a stabilized sample, converting the stabilized sample to a solid, adding one or more additives and/or excipients to the solid to form a treatment composition, and encapsulating the treatment composition.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: March 12, 2019
    Assignee: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Beth Anne-Szkudlarek Brown, Joshua Erickson
  • Patent number: 10221222
    Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: March 5, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Ziqing Jiang, Robert S. Hodges, Lajos Gera, Colin T. Mant
  • Patent number: 10221251
    Abstract: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: March 5, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Shirley Jane Peters
  • Patent number: 10213485
    Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: February 26, 2019
    Assignee: KRINGLE PHARMA INC.
    Inventors: Kazuhiro Fukuta, Hayao Inoue
  • Patent number: 10214582
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: February 26, 2019
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
  • Patent number: 10208325
    Abstract: Provided are a microorganism of the genus Corynebacterium having an enhanced activity to produce L-lysine as a result of inactivating a secretory protein and a method for producing L-lysine using the microorganism.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: February 19, 2019
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Peter Lee, Jun Ok Moon, Hyung Joon Kim, Song Gi Ryu
  • Patent number: 10208112
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: February 19, 2019
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
  • Patent number: 10196614
    Abstract: The present limiting provides compositions of CD 180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: February 5, 2019
    Assignee: University of Washington Through its Center for Commercialization
    Inventors: Edward Clark, Jay Wesley Chaplin
  • Patent number: 10195305
    Abstract: The present invention relates to a flowable bone graft material including an inorganic composition comprising calcium phosphate having a particle size of about 100 ?m to about 1,000 ?m, bioactive glass, and one or more biocompatible polymers comprising carboxymethyl cellulose and a fluid.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: February 5, 2019
    Assignee: Orthovita, Inc.
    Inventors: Alice Bachert, Jeremy Mercuri
  • Patent number: 10195569
    Abstract: Spin columns that include a poly(acid) membrane separation matrix are provided. Also provided are kits that include the subject devices, as well as methods of using the devices, e.g., in sample preparation (such as protein purification) protocols.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: February 5, 2019
    Assignee: TAKARA BIO USA, INC.
    Inventors: George G. Jokhadze, Sayantan Mitra
  • Patent number: 10189895
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: January 29, 2019
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
  • Patent number: 10183969
    Abstract: The present invention relates to a process for purification of a target molecule, comprising the steps: (a) contacting a target molecule, and a population of target binding polypeptides (TBP), in solution for a sufficient time to allow complex formation; and (b) isolating the target from the complex from (a) by subsequent purification steps, wherein (i) the target binding polypeptides have at least two binding functionalities; a first binding functionality towards the target and a second binding functionality towards a catching ligand comprised in a solid support; and (ii) the first binding functionality comprises at least two binding sites for the target, and the target comp¬ rises at least two binding sites for the TBP.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: January 22, 2019
    Assignee: CHRETO ApS
    Inventors: Jan Kyhse-Andersen, Lars Winther
  • Patent number: 10155800
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: December 18, 2018
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Patent number: 10149888
    Abstract: The present invention relates to a novel use of the HIV NC protein, and more particularly, it is relates to a pharmaceutical composition for preventing and treating AIDS having a polypeptide comprising HIV NC protein as an active component and the method of inhibiting HIV proliferation by using the polypeptide. The polypeptide comprising HIV NC protein of the present invention, when it is overexpressed, has the effect on inhibiting HIV proliferation. Accordingly, the present invention provides not only the novel means of inhibition of HIV proliferation, but also the novel method for preventing and treating AIDS.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: December 11, 2018
    Assignees: AVIXGEN INC.
    Inventor: Ji Chang You
  • Patent number: 10144917
    Abstract: The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (II): wherein: X is a —(CH2)-CO2Y group and Y is an alkaline metal or one of the pharmaceutically acceptable salts thereof, wherein said resulting vaccine antigen also includes a fragment of the biological membrane associated with said antigen. The present invention also relates to a vaccine that can be produced by implementing the method, including a calixarene of formula (II) in carrier format, with a quantity of 0.1 to 1,000 ?g in the total weight of the vaccine. The present invention further relates to the use of a calixarene as defined above for the preparation of a vaccine or a vaccine antigen, and to the vaccine for use as a drug in the treatment or prevention of an infectious disease.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: December 4, 2018
    Assignees: CALIXAR, UNIVERSITÉ CLAUD BERNARD LYON 1, HOSPICES CIVILS DE LYON, INSERM
    Inventors: Manuel Rosa-Calatrava, Aurélien Traversier, Élodie Desuzinges-Mandon, Emmanuel Dejean
  • Patent number: 10119975
    Abstract: Systems, methods, libraries, kits, and computer software tools are provided for designing and producing engineered cells. Such engineered cells can be used for cell state quantification, such as genome, transcriptome and/or proteome quantification. In one aspect, an engineered cell having a plurality of artificially designed oligonucleotides introduced into the genome of the cell is provided. The oligonucleotides are each located in proximity of a gene of interest encoding a protein of interest, and are different from one another. The oligonucleotides can each encode a unique peptide tag for each protein of interest, wherein each peptide tag has a unique quantitatively measurable value such as mass-to-charge ratio which can be quantified by a mass spectrometer. The engineered cell is capable of expressing a plurality of proteins of interest each fused to its corresponding unique peptide tag, wherein each peptide tag is capable of being released therefrom.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: November 6, 2018
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Reshma Shetty, Thomas F. Knight, Jr., Randall D. Rettberg
  • Patent number: 10086037
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: October 2, 2018
    Inventors: Tapas Das Gupta, Ananda Chakrabarty, Craig Beattie, Tohru Yamada
  • Patent number: 10065996
    Abstract: The invention concerns novel streptavidin muteins. In one embodiment such a mutein (a) contains at least one mutation in the region of the amino acid positions 115 to 121 with reference to the amino acid sequence of wild type streptavidin as set forth at SEQ ID NO: 15 and (b) has a higher binding affinity than each of (i) a streptavidin mutein that comprises the amino acid sequence Val44-Thr45-Ala46-Arg47 (SEQ ID NO: 98), or (ii) a streptavidin mutein that comprises the amino acid sequence He44-Gly45-Ala46-Arg47 (SEQ ID NO: 99) at amino acid positions 44 to 47, or (iii) wild type-streptavidin (SEQ ID NO: 15) for peptide ligands comprising the amino acid sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 100).
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: September 4, 2018
    Assignee: IBA GMBH
    Inventor: Thomas Schmidt
  • Patent number: 10059751
    Abstract: The invention relates to combinations of peptides or variants thereof derived from a portion of an amino sequence of a house dust mite allergen, e.g. the allergens Der p 1, Der f 1, Der p 2 and/or Der f 2. Such peptides comprise at least one T cell epitope and a significant high number of patients in a worldwide population will have HLA alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by a dust mite.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: August 28, 2018
    Assignees: ALK-ABELLÓ A/S, LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOGY
    Inventors: Claus Lundegaard, Lars Harder Christensen, Peter Adler Wurtzen, Alessandro Sette, John Sidney, Gitte Lund, Peter Sejer Andersen
  • Patent number: 10040841
    Abstract: A stable fusion protein, wherein in solution, a majority of the fusion proteins are in the homo-hexamer form, which may be prepared for example as a CTLA4-FasL fusion protein.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: August 7, 2018
    Assignee: KAHR Medical Ltd.
    Inventors: Michal Dranitzki Elhalel, Noam Shani
  • Patent number: 10036051
    Abstract: Nucleic acid sequences encoding chimeric polypeptides that exhibit enhanced cellulase activities are disclosed herein. These nucleic acids may be expressed in hosts such as fungi, which in turn may be cultured to produce chimeric polypeptides. Also disclosed are chimeric polypeptides and their use in the degradation of cellulosic materials.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: July 31, 2018
    Assignee: Alliance for Sustainable Energy, LLC
    Inventors: William S. Adney, Gregg T. Beckham, Eric Jarvis, Michael E. Himmel, Stephen R. Decker, Jeffrey G. Linger, Kara Podkaminer, John O. Baker, Larry Taylor, II, Qi Xu, Arjun Singh
  • Patent number: 10030099
    Abstract: The present invention relates to the chemical digestion of keratin, such as avian feathers and wool. The digestion product is made by heating the feathers or wool with a solvent selected from glycols, alkanolamines, polyamines, and combinations thereof. The resulting digested keratin product is a keratin-derived polyol useful for making polymeric materials such as polyurethanes. The digestion products provide a sustainable alternative to petrochemical based intermediates.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: July 24, 2018
    Assignee: Resinate Materials Group, Inc.
    Inventors: Rick Tabor, Eric David Vrabel, Matthew J Beatty, Jack Rogers Kovsky
  • Patent number: 10023653
    Abstract: Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumor cells that also express the putative tumor stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumor cells and also as a therapeutic agent for treating cancers, tumors and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumor, renal tumor, prostate cancer, sarcoma and/or melanoma.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: July 17, 2018
    Assignees: Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd.
    Inventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
  • Patent number: 10024854
    Abstract: The invention is based, in part, on the discovery that a polypeptide, referred to herein as Betacam, is selectively expressed on the surface of pancreatic islet cells. Thus, in one aspect, the invention is directed to compositions comprising Betacam or that can be used to detect Betacam. In another aspect, the invention provides methods of detecting (e.g., non-invasively) pancreatic beta cells from a mammalian cell source. Another aspect of the invention is directed to cellular purification of pancreatic beta cells from a heterogeneous cell source of multiple kinds. In another aspect, the invention provides methods of identifying agents that modulate activity of Betacam. In yet another aspect, the invention provides for improved treatment and diagnosis of diabetes.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: July 17, 2018
    Assignees: THE CLEVELAND CLINIC FOUNDATION, THE REGENT OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Jan Jensen, John Hutton, Xiaoling Qu, Howard Davidson
  • Patent number: 10023619
    Abstract: Methods for the production of synthetic spider silk-like proteins in corn endosperm, plant leaf or plant shoot tissue are provided. The present invention provides further methods for the identification of synthetic spider silk-like proteins in corn endosperm, plant leaf or plant shoot tissue.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: July 17, 2018
    Assignee: University of Wyoming
    Inventors: Randolph V. Lewis, David J. Perry
  • Patent number: 10017796
    Abstract: The invention relates to genetically modified organisms with enhanced production of omega-3 long chain polyunsaturated fatty acids.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: July 10, 2018
    Assignee: ROTHAMSTED RESEARCH LIMITED
    Inventors: Jonathan A. Napier, Olga Sayanova, Mary Hamilton, Royah Vaezi
  • Patent number: 9993521
    Abstract: Compositions and kits for modulating expression of scleraxis and/or collagen synthesis in mammalian cells and tissues. The compositions and kits comprise a protein comprising an amino acid sequence that shares at least 75% homology with SEQ ID NO:11. Proteins comprising amino acid sequences that share at least 75% homology with SEQ ID NO: 11 are expressed by mutants of scleraxis gene wherein a nucleotide sequence comprising a basic DNA binding domain has been deleted. Such mutants are exemplified by basic domain deletion Scx?BD mutants that comprise nucleotide sequences sharing at least 75% homology with SEQ ID NO:8 or SEQ ID NO: 10. Methods for modulating fibrosis in a subject comprising administration of a composition comprising at least one physiologically effective dosage of a protein comprising a polypeptide molecule comprising an amino acid sequence that shares at least 75% homology with SEQ ID NO: 11.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: June 12, 2018
    Assignee: University of Manitoba
    Inventor: Michael P. Czubryt
  • Patent number: 9994639
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumor growth.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: June 12, 2018
    Assignee: Ablynx N.V.
    Inventors: Francis Descamps, David Andre Baptiste Maussang-Detaille, Maarten Van Roy, Maria Gonzalez Pajuelo, Regorius Leurs, Pascal Gerard Merchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Peter Vanlandschoot
  • Patent number: 9975931
    Abstract: The inventors surprisingly found that an immunomodulatory protein from Ganoderma can promote neurite outgrowth, suggesting that the immunomodulatory protein from Ganoderma can treat and/or prevent neurological disorders. Accordingly, the invention provides a method for promoting neurite outgrowth, the method comprising exposing the neuron to an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof. The invention also provides a method for treating and/or preventing a neurological disorder, the method comprising administering an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof to a subject.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: May 22, 2018
    Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.
    Inventor: Ming-Wei Chao
  • Patent number: 9970946
    Abstract: The object of the present invention is to provide a marker substance capable of determining a risk of hyperglycemia in vivo with high accuracy. The present invention provides the following: a marker peptide for determining the risk of hyperglycemia; an antibody or an aptamer bound to the marker peptide for determining the risk of hyperglycemia; a microarray wherein the antibody or the aptamer to be bound to the marker peptide for determining the risk of hyperglycemia has been immobilized onto a carrier; a method of determining the risk of hyperglycemia wherein an amount or the presence/absence of the marker peptide for determining the risk of hyperglycemia is measured in a biological sample collected from a subject; and a kit for determining the risk of hyperglycemia comprising the antibody or the aptamer, or the microarray.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: May 15, 2018
    Assignee: LION CORPORATION
    Inventors: Chiyoko Uchiyama, Kei Kurita
  • Patent number: 9963721
    Abstract: Provided is a screening method of discovering genes capable of increasing 1,4-BDO production on the basis of proteomics data. Over-expression of proteins screened by the method, NCgl0630 (citrate synthase) and NCgl2145 (hypothetical protein), increase 1,4-BDO productivity. The method may lead to screening of a protein associated with 1,4-BDO productivity, thereby increasing 1,4-BDO productivity, and thus, the method may be recognized as being industrially applicable.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: May 8, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hwayoung Cho, Jinhwan Park, Yukyung Jung, Jaechan Park
  • Patent number: 9958363
    Abstract: A method for removing an ionic liquid from an aqueous sample is provided. In some embodiments, the method includes: (a) combining an aqueous sample including an ionic liquid with an ion exchanger composition including an ion exchanger counterion to produce a solution including a fluorous salt of the ionic liquid, where at least one of the ionic liquid and the ion exchanger counterion is fluorinated; (b) contacting the solution with a fluorous affinity material, thereby removing fluorous salt from the solution and producing an aqueous eluate; and (c) collecting the aqueous eluate. In certain embodiments, the method further includes: contacting a cell with an ionic liquid composition to lyse the cell and produce an aqueous sample; and contacting the aqueous sample with a reverse phase substrate, thereby adsorbing proteins and/or lipids of the cell on the substrate. Compositions, kits and systems for practicing the subject methods are also provided.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: May 1, 2018
    Assignee: Agilent Technologies, Inc.
    Inventors: Brian Phillip Smart, Brooks Bond-Watts, James Alexander Apffel, Jr.
  • Patent number: 9950070
    Abstract: This invention relates to a complex for cancer cell chemotherapy and, more particularly, to a HER2 aptamer-anticancer drug complex for chemotherapy of cancer cells, which includes a nucleic acid aptamer specifically binding to HER2 and an anticancer drug linked with the nucleic acid aptamer, so that HER2-positive breast cancer cells are selectively targeted and killed.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: April 24, 2018
    Assignee: Korea University Research and Business Foundation
    Inventors: Jae-Hong Seo, Chang-Ill Ban, Hun-Ho Jo, Ji-Young Kim, Young-Kwan Cho
  • Patent number: 9945866
    Abstract: Disclosed herein is a protein standard for gel electrophoresis. The standard may be detected using multiple modalities. These modalities include, for example, observation of color or fluorescence arising from dyes, porphyrins, or haloalkylated tryptophan residues covalently linked to proteins of the standard; or detection of fluorescence or chemiluminescence arising from antibodies or other binding partners bound to proteins of the standard through polypeptide epitopes or affinity tags. The protein standard comprises multiple protein sets, each set corresponding to a different gel band, and proteins within a set may be detectable with one or more modalities.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 17, 2018
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Joseph S. Siino, Jr., Dennis C. Yee, Robin Baginski
  • Patent number: 9944689
    Abstract: Mutant forms of human CTLA4, and their use, e.g., in xenotransplantation.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: April 17, 2018
    Assignee: The General Hospital Corporation
    Inventors: Zhirui Wang, Christene A. Huang, David H. Sachs
  • Patent number: 9937226
    Abstract: The present invention relates to a new use of an immunomodulatory protein derived from Ganoderma or a recombinant or a composition thereof in inhibiting cancel stem cells. Particularly, the immunomodulatory protein is derived form Ganoderma microsporum and the cancel stem cell is oral cancer stem cell.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: April 10, 2018
    Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.
    Inventor: Cheng-Chia Yu
  • Patent number: 9938331
    Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: April 10, 2018
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Nathaniel C. Gordon, Andreas Crameri, Mikhail Popkov
  • Patent number: 9931385
    Abstract: The present invention provides a method of inhibiting maturation of the gonads of a juvenile animal which comprises administering to said juvenile animal an immunologically active molecule (IAM) or a vector comprising nucleic acid encoding an immunologically active molecule, said IAM being specific for a target protein within the gonads and binding thereto or causing an immune response against that target protein, and thereby inhibiting maturation of the gonads, as well as molecules of use in such methods.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: April 3, 2018
    Assignee: University of Nordland
    Inventors: Igor Babiak, Reid Hole
  • Patent number: 9926378
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: March 27, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ole Petter Veiby, John S. Babcook
  • Patent number: 9926587
    Abstract: The present invention relates to the use, notably cosmetic and/or therapeutic, of the YKL-40 protein belonging to the family of chitinase-type proteins, of polypeptides derived from this protein or analogs thereof of a nucleic acid sequence encoding such a polypeptide or of an agent that modulates the activity or expression of such a polypeptide notably for stimulation of terminal epithelial differentiation.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: March 27, 2018
    Assignee: L'OREAL
    Inventors: Dominique Bernard, Mark Donovan
  • Patent number: 9920381
    Abstract: Methods for the rapid detection of the presence or absence of mecC-containing Staphylococcus aureus (mecC-MRSA) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the genes for mecC-MRSA, along with kits are provided that are designed for the detection of mecC-MRSA.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 20, 2018
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Jenny A. Johnson, Ashley Hayes
  • Patent number: 9920297
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein 1. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: March 20, 2018
    Assignee: VAXIMM AG
    Inventors: Heinz Lubenau, Marco Springer
  • Patent number: 9913885
    Abstract: Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: March 13, 2018
    Inventors: David Weiner, Jian Yan, Bernadette Ferraro, Niranjan Y. Sardesai, Mathura P. Ramanathan
  • Patent number: 9915667
    Abstract: Provided herein are methods for diagnosing the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like giant-cell arteritis (GCA), polymyalgia rheumatica (PMR), and Takayasu's arteritis, in a subject analyzing for the presence of antibodies against ferritin, in particular heavy chain ferritin or immunoreactive peptides thereof or ferritin analog protein, preferably bacterial ferritin analog protein, or immunoreactive peptides thereof, in a subject. In addition, test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject are also provided.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: March 13, 2018
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Torsten Witte, Niklas Thomas Baerlecken
  • Patent number: 9902759
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: February 27, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Patent number: 9897611
    Abstract: Disclosed is a molecular library comprising a group of a plurality of molecules, wherein each member of the library is a polypeptide having a randomized sequence moiety and a microprotein moiety. The microprotein is a protein comprising an amino acid sequence of 30 or less amino acid residues having the ability to form a particular conformation by spontaneous folding in a solution and is, for example, chignolin comprising the amino acid sequence represented by SEQ ID NO: 1. Also, disclosed is a method for identifying a novel functional molecule using the library of the present invention.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: February 20, 2018
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Shinya Honda, Hideki Watanabe, Kazuhiko Yamasaki
  • Patent number: 9884903
    Abstract: B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: February 6, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Lieping Chen